Comparison study of two commercially available methods for the determination of infliximab, adalimumab, etanercept and anti-drug antibody levels

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 12, 2013, Pages

  Ruiz Argüello, Begoña ^a   Del Agua, Ainhoa Ruiz ^a   Torres, Nerea ^a   Monasterio, Alberto ^a   Martínez, Antonio ^a   Nagore, Daniel ^a  

^a Proteomika S L Parque Tecnológico de Bizkaia   (Spain)

Author keywords

Anti TNF drugs; Biological drug monitoring; Immunogenicity; Method comparison

Indexed keywords

ADALIMUMAB; DRUG ANTIBODY; ETANERCEPT; INFLIXIMAB; RADIOISOTOPE; TUMOR NECROSIS FACTOR INHIBITOR;

ANALYTIC METHOD; ANTIBODY BLOOD LEVEL; AUTOMATION; CELL ASSAY; DRUG DETERMINATION; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOSUPPRESSIVE TREATMENT; INTERMETHOD COMPARISON; LETTER; LIMIT OF QUANTITATION; MEASUREMENT ACCURACY; PATIENT MONITORING; PRIORITY JOURNAL; RADIOIMMUNOASSAY; SENSITIVITY AND SPECIFICITY;

ANTIBODIES; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; IMMUNOGLOBULIN G; REAGENT KITS, DIAGNOSTIC; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 84889601630     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2013-0461     Document Type: Letter

References (10)

1. van Schouwenburg PA, Rispens T, Wolbink GJ. Immunogenicity of anti-TNF biologic therapies for rheumatoid arthritis. Nat Rev Rheumatol 2013;9: 164-72.
2. Plasencia C, Pascual-Salcedo D, Nuño L, Bonilla G, Villalba A, Peiteado D, et al. Influence of immunogenicity on the efficacy of long-term treatment of spondyloarthritis with infliximab. Ann Rheum Dis 2012;71: 1955-60.
3. Pascual-Salcedo D, Plasencia C, Ramiro S, Nuno L, Bonilla G, Nagore D, et al. Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology 2011;50: 1445-52.
4. Llinares-Tello F, de Salazar JR, Gallego JM, Soler GS, Ramirez CS, Heredia ES, et al. Analytical and clinical evaluation of a new immunoassay for therapeutic drug monitoring of infliximab and adalimumab. Clin Chem Lab Med 2012;50: 1845-7.
5. Jamnitski A, Bartelds GM, Nurmohamed MT, van Schouwenburg PA, van SD, Stapel SO, et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis 2011;70: 284-8.
6. Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcelli C. Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013;72: 165-78.
7. Emi Aikawa N, de Carvalho JF, Artur Almeida SC, Bonfa E. Immunogenicity of anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol 2010;38: 82-9.
8. Gorovits B. Antidrug antibody assay validation: industry survey results. AAPS J 2009;11: 133-8.
9. Garcês S, Antunes M, Benito-Garcia E, da Silva JC, Aarden L, Demengeot J. A preliminary algorithm introducing immunogenicity assessment in the management of patients with RA receiving tumour necrosis factor inhibitor therapies. Ann Rheum Dis 2013. Epub ahead of print 11 May 2013. DOI: 10.1136/annrheumdis.2013.203296.
10. Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal 2008;48: 1267-81.